polysaccharide vaccine, and antibiotic prophylaxis .
Pediatrics. 2000;106:362-366
28. Hausdorff WP, Bryant J, Paradiso PR, Siber GR – W hich
pneumococcal serogroups cause the most invasive disease:
implications for conjugate vaccine formulation and use, part I.
Clin Infect Dis. 2000;30:100-121
29. Black S, Shinefield H, Fireman B, et al – Efficacy, safety, and
immunogenicity of heptavalent pneumococcal conjugate
vaccine in children. Pediatr Infect Dis J. 2001;20:1105-1107
30. Lin PL, Michaels MG, Janosky J, Ortenzo M, Wald ER, Mason
EO – Incidence of invasive pneumococcal disease in children
3 to 36 months of age at a tertiary care pediatric center 2 to
years after licensure pneumococcal conjugate vaccine.
Peditrics. 2003;111:896-899
31. Whitney CG, Farley MM, Hadler J, et al – Decline in invasive
pneumococcal disease after the introduction of protein-
polysaccharide conjugate vaccine. N Engl J Med.
2003;348:1737-1746
32. Baraff LJ, Bass JW, Fleisher GR, et al – Practice guideline for
the management of infants and children 0 to 36 months of age
with fever without sourse. Pediatrics 1993;92:1-12
33. McCarthy PL, Sharpe MR, Spiesel SZ, et al – Observation
scales to identify serious illness in febrile children.
Pediatrics. 1992;70:802-809
34. Baraff LJ , Oslund S, Schriger DL, Stephen ML. – Probability
of bacterial infections in infants less than three months of
age:a meta-analysis. Pediatr Infect Dis J.1992;11:257-265
35. Dagan R, Powell KR, Hall CB, Menegus MA – Identification of
infants unlikely to have serius bacterial infection although
hospitalized for suspected sepsis. J Pediatr. 1985:107:855-
860